The DOI matches its Crossref record; 506 of the 506 references it cites were found in a registry or an index.
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Open accessAbstract
Drug designing and development is an important area of research for pharmaceutical companies and chemical scientists. However, low efficacy, off-target delivery, time consumption, and high cost impose a hurdle and challenges that impact drug design and discovery. Further, complex and big data from genomics, proteomics, microarray data, and clinical trials also impose an obstacle in the drug discovery pipeline. Artificial intelligence and machine learning technology play a crucial role in drug discovery and development. In other words, artificial neural networks and deep learning algorithms have modernized the area. Machine learning and deep learning algorithms have been implemented in several drug discovery processes such as peptide synthesis, structure-based virtual screening, ligand-based virtual screening, toxicity prediction, drug monitoring and release, pharmacophore modeling, quantitative structure-activity relationship, drug repositioning, polypharmacology, and physiochemical activity. Evidence from the past strengthens the implementation of artificial intelligence and deep learning in this field. Moreover, novel data mining, curation, and management techniques provided critical support to recently developed modeling algorithms. In summary, artificial intelligence and deep learning advancements provide an excellent opportunity for rational drug design and discovery process, which will eventually impact mankind. The primary concern associated with drug design and development is time consumption and production cost. Further, inefficiency, inaccurate target delivery, and inappropriate dosage are other hurdles that inhibit the process of drug delivery and development. With advancements in technology, computer-aided drug design integrating artificial intelligence algorithms can eliminate the challenges and hurdles of traditional drug design and development. Artificial intelligence is referred to as superset comprising machine learning, whereas machine learning comprises supervised learning, unsupervised learning, and reinforcement learning. Further, deep learning, a subset of machine learning, has been extensively implemented in drug design and development. The artificial neural network, deep neural network, support vector machines, classification and regression, generative adversarial networks, symbolic learning, and meta-learning are examples of the algorithms applied to the drug design and discovery process. Artificial intelligence has been applied to different areas of drug design and development process, such as from peptide synthesis to molecule design, virtual screening to molecular docking, quantitative structure-activity relationship to drug repositioning, protein misfolding to protein-protein interactions, and molecular pathway identification to polypharmacology. Artificial intelligence principles have been applied to the classification of active and inactive, monitoring drug release, pre-clinical and clinical development, primary and secondary drug screening, biomarker development, pharmaceutical manufacturing, bioactivity identification and physiochemical properties, prediction of toxicity, and identification of mode of action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Artificial Intelligence may allow for more accurate personalisation of therapy to predict the optimum ‘cocktail’ of mono agonist therapies based on the genetics and metabolomics of an individual and may quicken the process of drug development [70, 71].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [71]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These authors trained a DL algorithm on a large dataset of known cancer-related compounds and their corresponding biological activity. As an output, novel compounds with high potential for future cancer treatment were obtained, demonstrating the ability of this method to discover new therapeutic candidates.”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, the successful use of AI to identify novel compounds for the treatment of cancer has recently been reported by Gupta, R., et al. [21].”
From The role of AI in drug discovery: challenges, opportunities, and strategies (2023) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ImageNet classification with deep convolutional neural networks
Krizhevsky, A., Sutskever, I., & Hinton, G. E. (2017) · Communications of the ACM · doi:10.1145/3065386 · Cited by 112,155 · cited 1×
“AlexNet, a convolutional neural network, was created by Alex Krizhevsky around 2012, which helped in strengthening the speed and dropout using rectified linear units [33].”
MethodHochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318 · cited 1×
“After two years, in 1997, Jürgen Schmidhuber and Sepp Hochreiter developed long short-term memory (LSTM) for recurrent neural networks [30].”
BackgroundLeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
ImageNet: A large-scale hierarchical image database
Deng, J., Dong, W., Socher, R., Li, L.-J., Li, K., & Fei-Fei, L. (2009) · 2009 IEEE Conference on Computer Vision and Pattern Recognition · doi:10.1109/cvpr.2009.5206848 · Cited by 65,333 · cited 1×
“In 2009, Fei-Fei Li launched ImageNet, which is a free database containing millions of labeled images that can be used for research purposes [32].”
BackgroundCortes, C., & Vapnik, V. (1995) · Machine Learning · doi:10.1007/bf00994018 · Cited by 59,421
Cortes, C., & Vapnik, V. (1995) · Machine-mediated learning · doi:10.1023/a:1022627411411 · Cited by 48,374 · cited 1×
“In 1995, Corinna Cortes and Vladimir Vapnik developed support vector machines (SVM) to map and recognize similar data [29].”
BackgroundLearning representations by back-propagating errors
Rumelhart, D. E., Hinton, G. E., & Williams, R. J. (1986) · Nature · doi:10.1038/323533a0 · Cited by 31,892 · cited 1×
“David Rumelhart, Geoffrey Hinton, and Ronald J. Williams published a paper entitled “Learning Representations by Back-propagating Errors” in 1986, which demonstrated that backpropagation could provide an improvement in shape recognition and word prediction [26].”
BackgroundAdvances in neural information processing systems 7
Cios, K., & Shields, M. (1997) · Neurocomputing · doi:10.1016/s0925-2312(97)90018-7 · Cited by 22,059
Deep learning in neural networks: an overview
Schmidhuber, J. (2015) · Neural Networks · doi:10.1016/j.neunet.2014.09.003 · Cited by 18,570 · cited 1×
“…uses supervised learning, where the model is trained to use labeled data, which means that the input has been tagged with corresponding preferred output labels or uses unsupervised learning, where the model is trained to use unlabeled data but looks for recurring patterns from the input data [15].”
A logical calculus of the ideas immanent in nervous activity
McCulloch, W. S., & Pitts, W. (1943) · The Bulletin of Mathematical Biophysics · doi:10.1007/bf02478259 · Cited by 18,566
Research works printed but not linked: 5
- Carpenter KA, Huang X (2018) Machine learning-based virtual screening and its applications to Alzheimer’s drug discovery: a review. Curr Pharm Des. https://doi.org/10.2174/1381612824666180607124038 · DOI · Paper page
- Gad SC (2014) QSAR. In: Third E (ed) Wexler PBT- Encyclopedia of Toxicology. Academic Press, Oxford, pp 1–9
- Royal Society of Chemistry (2015) ChemSpider. Search and Share Chemistry. R. Soc, Chem
- Cao X, Fan R, Zeng W (2020) DeepDrug: a general graph-based deep learning framework for drug relation prediction. biorxiv. https://doi.org/10.1101/2020.11.09.375626 · DOI
- Harrer S, Shah P, Antony B, Hu J (2019) Artificial intelligence for clinical trial design. Trends Pharmacol Sci 40:577–591. https://doi.org/10.1016/j.tips.2019.05.005 · DOI · Paper page
Cited by
The Role of AI in Hospitals and Clinics: Transforming Healthcare in the 21st Century
Maleki Varnosfaderani, S., & Forouzanfar, M. (2024) · Bioengineering · doi:10.3390/bioengineering11040337 · Cited by 931
“By analyzing historical data from clinical trials and patient records, AI models can predict the effectiveness of drugs on various demographic groups [44,45].”
MethodThe role of AI in drug discovery: challenges, opportunities, and strategies
Blanco-González, A., Cabezón, A., Seco-González, A., Conde-Torres, D., Antelo-Riveiro, P., Piñeiro, Á., & Garcia-Fandino, R. (2023) · Pharmaceuticals · doi:10.3390/ph16060891 · Cited by 690
Targeting ferroptosis opens new avenues for the development of novel therapeutics
Sun, S., Shen, J., Jiang, J., Wang, F., & Min, J. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01606-1 · Cited by 608
“Today, AI-based technologies have been applied to virtually every step in the drug discovery process, including target identification, drug design, drug screening, chemical synthesis, and prediction of the drug’s properties and mode of action.(341,342) In addition, AI can be used to quickly identify lead compounds ext…”
Metaverse for Healthcare: A Survey on Potential Applications, Challenges and Future Directions
Chengoden, R., Victor, N., Huynh-The, T., Yenduri, G., Jhaveri, R. H., Alazab, M., Bhattacharya, S., Hegde, P., Maddikunta, P. K. R., & Gadekallu, T. R. (2023) · IEEE Access · doi:10.1109/access.2023.3241628 · Cited by 508
“Artificial intelligence (AI), also known as machine intelligence, focuses on the development and management of technology that can autonomously learn to make decisions and carry out tasks on behalf of humans [90].”
BackgroundClinical trial design in the era of precision medicine
Fountzilas, E., Tsimberidou, A. M., Vo, H. H., & Kurzrock, R. (2022) · Genome Medicine · doi:10.1186/s13073-022-01102-1 · Cited by 305
“Machine-learning and AI technology have the potential to accelerate the process of drug development, reducing failure rates, and increasing the accuracy of predictions [20, 177].”
Background
Metadata
- Authors
- Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P.
- Affiliations
- Delhi Technological University (IN)
- Corresponding author
- Kumar, Pravir
- Venue
- Molecular Diversity
- Published
- 2021-04-12
- Volume
- 25
- Issue
- 3
- Pages
- 1315-1360
- ISSN
- 1381-1991 (ISSN-L)
- 1573-501X
- PMC
- PMC8040371
- OpenAlex
- W3153418506
- Semantic Scholar
- 29409efa04ac99ccf01d2a011d21d5d14e870000
- Cited by
- 1,473
- References
- 503
- Citations by year
- 2026: 221 · 2025: 438 · 2024: 397 · 2023: 272 · 2022: 113 · 2021: 31
- FWCI
- 15.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Molecular Diversity (publishedVersion, cc-by)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Physical Sciences › Materials Science › Materials Chemistry › Machine Learning in Materials Science
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- artificial intelligence in drug discovery, deep learning, computer-aided drug design, virtual screening, structure-based virtual screening, ligand-based virtual screening, QSAR, pharmacophore modeling, drug repurposing, polypharmacology, toxicity prediction, generative adversarial networks, molecular docking, protein misfolding, biomarker development, drug release monitoring
- MeSH terms
- Machine Learning, Drug Development, Deep Learning, Big Data, Algorithms, Animals, Artificial Intelligence, Humans, Models, Molecular, Research Design, Drug Design, Quantitative Structure-Activity Relationship, Drug Discovery, Data Mining, Chemistry Techniques, Synthetic, Support Vector Machine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Artificial intelligence to deep learning: machine intelligence approach for drug discovery. https://app.cochat.ai/papers/10.1007/s11030-021-10217-3
- The paper
- Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021). Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular Diversity. https://doi.org/10.1007/s11030-021-10217-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.